Patricia Bastick

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2024 · 155 citations

Medicine, Oncology, Pharmacology +12

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue

Carolina X. Sandler, David Goldstein, Sarah Horsfield et al. · Journal of Pain and Symptom Management · 2017 · 63 citations · Full text

Medicine, Oncology, Rehabilitation Medicine +16

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

Hui‐Ming Lin, Kate Mahon, Calan Spielman et al. · British Journal of Cancer · 2017 · 57 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity

Shom Goel, Jia Liu, Hao Guo et al. · JACC Heart Failure · 2019 · 51 citations

Medicine, Cardiology, Oncology +17